Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RENEW-MDD 1: Brenipatide Adjunctive Therapy in Major Depressive Disorder
jRCT2021250055Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2026
- Modality
- Peptides
01
Overview
Phase 3, randomised, double-blind trial of brenipatide in major depressive disorder (MDD) (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Time to relapse of major depressive disorder. Started Apr 2026; status: recruiting.
02
Drugs
brenipatide
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on jRCT2021250055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021250055.